Wells Fargo’s Better Therapeutics, Inc. Common Stock BTTX Stock Holding History

Wells Fargo’s Portfolio BTTX Stock Details BTTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-179	Closed	-$35	–	7769
2023 Q4	$35	Buy	179 +58	+48%	+$13	﹤0.01%	7034
2023 Q3	$44	Buy	121 +4	+3%	+$3	﹤0.01%	6956
2023 Q2	$126	Buy	117 +60	+105%	+$58	﹤0.01%	6824
2023 Q1	$40	Hold	57	–	–	﹤0.01%	7174
2022 Q4	$63	Buy	57 +2	+4%	+$3	﹤0.01%	6936
2022 Q3	$0	Sell	55 -10	-15%	-$18	﹤0.01%	7633
2022 Q2	$0	Buy	65 +5	+8%	+$8	﹤0.01%	7747
2022 Q1	$0	Buy	60 +1	+2%	+$3	﹤0.01%	8080
2021 Q4	$0	Buy	+59	New	+$484	﹤0.01%	8024

Other funds holding BTTX

CIAS

Capital Investment Advisory Services Raleigh, North Carolina $1.62B AUM 27.01% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

APC

Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return

Wells Fargo's BTTX Position: Q1 2024 in Review

Wells Fargo sold out of Better Therapeutics, Inc. Common Stock (BTTX) in Q1 2024, closing a stake of 179 shares — an estimated $35 sold.

Wells Fargo first reported a position in BTTX in Q4 2021 and held it in 9 quarters. The position peaked at $126 in Q2 2023. 3 funds tracked by Wall St. Rank hold BTTX as of Q1 2024.

Wells Fargo reported no remaining Better Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Wells Fargo sold 179 Better Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $35.
Wells Fargo first reported a position in Better Therapeutics, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
Wells Fargo's Better Therapeutics, Inc. Common Stock position peaked at $126 in Q2 2023.
3 funds tracked by Wall St. Rank held Better Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Wells Fargo's 13F filing for Q1 2024, filed 10 May 2024.